Cargando…

Laquinimod treatment in the R6/2 mouse model

The transgenic mouse model R6/2 exhibits Huntington’s disease (HD)-like deficits and basic pathophysiological similarities. We also used the pheochromocytoma-12 (PC12)-cell-line-model to investigate the effect of laquinimod on metabolic activity. Laquinimod is an orally administered immunomodulatory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellrichmann, Gisa, Blusch, Alina, Fatoba, Oluwaseun, Brunner, Janine, Reick, Christiane, Hayardeny, Liat, Hayden, Michael, Sehr, Dominik, Winklhofer, Konstanze F., Saft, Carsten, Gold, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504033/ https://www.ncbi.nlm.nih.gov/pubmed/28694434 http://dx.doi.org/10.1038/s41598-017-04990-1

Ejemplares similares

Author Correction: Laquinimod treatment in the R6/2 mouse model
por: Ellrichmann, Gisa, et al.
Publicado: (2019)

The Role of the Immune System in Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2013)

Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
por: Ellrichmann, Gisa, et al.
Publicado: (2011)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study
por: Stasiolek, Mariusz, et al.
Publicado: (2015)

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling
por: Kramann, Nadine, et al.
Publicado: (2016)

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
por: Mishra, Manoj Kumar, et al.
Publicado: (2014)

Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells
por: Grüter, Thomas, et al.
Publicado: (2020)

Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
por: Moore, Spencer, et al.
Publicado: (2013)

Positive effect of immunomodulatory therapies on disease progression in Huntington’s disease? Data from a real-world cohort
por: Achenbach, Jannis, et al.
Publicado: (2022)

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
por: Brück, Wolfgang, et al.
Publicado: (2012)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
por: Schneider-Gold, Christiane, et al.
Publicado: (2017)

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
por: Garcia-Miralles, Marta, et al.
Publicado: (2016)

Insight into Metabolic (1)H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
por: Schneider, Ruth, et al.
Publicado: (2017)

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model
por: Wilmes, Anna T., et al.
Publicado: (2018)

Laquinimod in the treatment of multiple sclerosis: a review of the data so far
por: Thöne, Jan, et al.
Publicado: (2016)

Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease
por: Lee, De-Hyung, et al.
Publicado: (2014)

Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea
por: Li, Zuohong, et al.
Publicado: (2020)

Laquinimod Supports Remyelination in Non-Supportive Environments
por: Nyamoya, Stella, et al.
Publicado: (2019)

Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model
por: Katsumoto, Atsuko, et al.
Publicado: (2018)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
por: Kolb-Sobieraj, Channa, et al.
Publicado: (2014)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation
por: Ellrichmann, Gisa, et al.
Publicado: (2012)

Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake
por: Gentile, Antonietta, et al.
Publicado: (2018)

A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2023)

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits
por: Thöne, Jan, et al.
Publicado: (2013)

Brainstem Encephalitis With Low-Titer Acetylcholine Receptor Antibodies Mimicking Myasthenia Gravis
por: Ayzenberg, Ilya, et al.
Publicado: (2019)

Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosis
por: Dohrn, Maike F., et al.
Publicado: (2021)

Targeting “bad” B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?
por: Forsthuber, Thomas G., et al.
Publicado: (2016)

Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS
por: Rothhammer, Veit, et al.
Publicado: (2021)

Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
por: Ellrichmann, Gisa, et al.
Publicado: (2018)

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression
por: Varrin-Doyer, Michel, et al.
Publicado: (2016)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

Laquinimod Modulates Human Astrocyte Function and Dampens Astrocyte-Induced Neurotoxicity during Inflammation
por: Colombo, Emanuela, et al.
Publicado: (2020)

Transcriptomic Impact of IMA-08401, a Novel AHR Agonist Resembling Laquinimod, on Rat Liver
por: Prokopec, Stephenie D., et al.
Publicado: (2019)

Error Processing in Huntington's Disease
por: Beste, Christian, et al.
Publicado: (2006)

Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS
por: Engel, Sinah, et al.
Publicado: (2020)

Evidences for Mutant Huntingtin Inducing Musculoskeletal and Brain Growth Impairments via Disturbing Testosterone Biosynthesis in Male Huntington Disease Animals
por: Yu-Taeger, Libo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mk8t1shd00avueg19slrqsp9q9